922P - Adjuvant chemotherapy using taxane plus carboplatin for stage IB-IIB cervical non-squamous cell carcinoma with pathologic high-risk factor

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anti-Cancer Agents & Biologic Therapy
Cervical Cancer
Presenter Seiya Sato
Citation Annals of Oncology (2014) 25 (suppl_4): iv305-iv326. 10.1093/annonc/mdu338
Authors S. Sato1, M. Shimada2, T. Ohta3, T. Kojimahara3, H. Tokunaga4, T. Takano5, S. Yamaguchi6, K. Fujiwara6, H. Tanabe7, A. Okamoto7, S. Nishio8, K. Ushijima8, M. Futagami9, Y. Yokoyama9, H. Fujimoto10, H. Nakamura11, T. Nakamura12, M. Moriyama13, Y. Kai14, J. Kigawa15
  • 1Obstetrics And Gynecology, Tottori University School of Medicine, 683-8504 - Yonago/JP
  • 2Obstetrics And Gynecology, Tottori University, Yonago/JP
  • 3Obstetrics And Gynecology,, Yamagata University Faculty of Medicine, Yamagata/JP
  • 4Obstetrics And Gynecology, Tohoku University Graduate School of Medicine, Sendai/JP
  • 5Clinical Reserch, Innovation, And Education Center, Tohoku University Hospital, Sendai/JP
  • 6Gynecologic Oncology, Hyogo Cancer Center, Akashi/JP
  • 7Obstetrics And Gynecology, Jikei University School of Medicine, 105-8461 - Tokyo/JP
  • 8Gynecologic Oncology, Kurume University School of Medicine, 8300011 - Kurume/JP
  • 9Obstetrics And Gynecology, Graduate School of Medicine Hirosaki University, Hirosaki/JP
  • 10Obstetrics And Gynecology, JA Hiroshima Kouseiren Hospital, Hiroshima/JP
  • 11Obstetrics And Gynecology, National Hospital Organization Kure Medical Center, Kure/JP
  • 12Obstetrics And Gynecology, Kagoshima City Hospital, Kagoshima/JP
  • 13Obstetrics And Gynecology, Shimane Prefectural Central Hospital, Izumo/JP
  • 14Obstetrics And Gynecology, Japanese Red Cross Kochi Hospital, Kochi/JP
  • 15Obstetrics And Gynecology, Matsue City Hospital, Matsue/JP

Abstract

Aim

Non-squamous cell carcinoma (non-SCC) of the uterine cervix is typically treated in a similar manner to SCC. Recent literatures suggested that adjuvant concurrent chemoradiotherapy with cisplatin could not improve the survival of pathologic high-risk patients with non-SCC. We conducted this pilot study to evaluate the efficacy and safety of adjuvant chemotherapy (AC) using taxane plus carboplatin (CBDCA) for stage IB-IIB cervical non-SCC with pathologic high-risk factor.

Methods

Between July 2008 and October 2013, 35 patients were enrolled in this study. One patient was ineligible because her histology was neuroendocrine tumor. All patients were classified as the pathologic high-risk group, which had positive lymphnode (PLN) and/ or positive parametrium (PP), after surgical findings. The patients were treated with 6 courses of docetaxel (60 mg/m2) or paclitaxel (175 mg/m2) followed by CBDCA (AUC= 6) on day 1 by intravenous infusion, and the protocol- scheduled treatment was repeated every 3 weeks. Primary endpoint was 2-year progression free survival (PFS) rate, and secondary endpoint was adverse events.

Results

The median age was 44 years (range 30–64). The histologic diagnoses were mucinous adenocarcinoma in 20 patients (58.8%), adenosquamous carcinoma in 8 (23.5%), and endometrioid adenocarcinoma in 2 (5.9%), clear cell carcinoma, adenoma malignum, poorly differentiated adenocarcinoma, and unclassified adenocarcinoma in 1 (2.9%), respectively. PLN were seen in 24 (70.6%), PP in 5 (14.7%), and both in 5 (14.7%). Among 34 patients, 24 patients (70.5%) were completed the 6cycles of AC. With a median follow-up of 2.4 years, 10 patients (29.4%) have relapsed. The 2-year cumulative PFS rate was 77.8% (95% CI: 59.0% to 88.8%). Grade 3 or 4 hematologic toxicities were neutropenia (79.4%), leukopenia (55.8%), anemia (20.5%), and thrombocytopenia (17.6%). The most frequent grade 3 or 4 nonhematologic toxicities were anorexia (5.9%), arthralgia (5.9%) and febrile neutropenia (5.9%).

Conclusions

The results of this pilot study showed an efficacy and safety of AC using taxan and CBDCA for locally advanced non-SCC of the cervix.

Disclosure

All authors have declared no conflicts of interest.